Kumar Parag, Thudium Emily, Laliberte Kevin, Zaccardelli David, Nelsen Andrew
United Therapeutics Corporation, 55 T.W. Alexander Drive, PO Box 14186, Research Triangle Park, NC, 27709, USA.
Clinical Pharmacokinetics Research Laboratory, National Institutes of Health, Bethesda, MD, USA.
Clin Pharmacokinet. 2016 Dec;55(12):1495-1505. doi: 10.1007/s40262-016-0409-0.
Treprostinil is available in three different formulations and four different routes of administration: Remodulin (treprostinil sodium, intravenous and subcutaneous administration), Tyvaso (treprostinil sodium, inhaled administration), and Orenitram (treprostinil diolamine, oral administration) for the treatment of pulmonary arterial hypertension (PAH). Pharmacokinetic studies have been performed in healthy volunteers and patients with PAH. The intent of this review is to outline pharmacokinetic considerations of the three treprostinil formulations and provide clinicians with a resource that may support clinical decisions in treating patients with PAH.
瑞莫杜林(曲前列尼尔钠,静脉和皮下给药)、全可利(曲前列尼尔钠,吸入给药)和奥伦特拉(曲前列尼尔二醇胺,口服给药),用于治疗肺动脉高压(PAH)。已在健康志愿者和PAH患者中进行了药代动力学研究。本综述的目的是概述三种曲前列尼尔剂型的药代动力学注意事项,并为临床医生提供一种资源,以支持其在治疗PAH患者时做出临床决策。